Tuberculosis: Opinions - Sci Forschen

Full Text

Opinion Article
Neutrophils as Possible Therapeutic Targets in Severe Influenza Pneumonia

  Teluguakula Narasaraju*      Ashar Harshini   

Center for Veterinary Health Sciences, Oklahoma State University, Oklahoma, USA

*Corresponding author: Teluguakula Narasaraju, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma, USA, E-mail: narasa@okstate.edu


The threat of pandemic and highly pathogenic influenza viruses currently represents a top global public health problem. Majority of deaths in patients with severe influenza infections are due to complications resulting from impaired gas-exchange, pulmonary edema and alveolarcapillary damage, which are characteristics of acute respiratory distress syndrome (ARDS) [1,2]. Although vaccination is the ultimate choice for preventing outbreaks and further pandemic spread of the virus, due to emergence of novel strains and the mutative ability of these viruses, effective vaccine is quite challenging. Treatment of infection using antiviral agents alone is not always effective due to the emergence of drug resistant viral strains and adverse effects associated with antiviral drug treatments [3,4]. Both virus and host-mediated factors contribute to lung pathology in influenza thus, a therapeutic approach targeting both the virus and the host response is desirable [5,6]. Among host factors, cytokine storm and aggravated hyper-inflammatory responses are linked with pulmonary damage and respiratory failure.

Neutrophils are short-lived and terminally differentiated cells of innate immune system. Although excessive neutrophil influx has been well described in pathologic development of acute lung injury, the role of neutrophils in influenza pathogenesis is not completely understood. Tate et al. [7] described beneficial effects of neutrophils by clearing the virus during influenza virus infection in mice. However, several studies have found neutrophilic predominant infiltrations within damaged lungs following several highly pathogenic influenza viral infections [8-10]. Our studies using mouse models have found that excessive neutrophil influx and neutrophil extracellular traps (NETs) contribute to immunopathology in influenza [11-14]. Based on our findings we hypothesize that targeting neutrophil-mediated acute lung injury together with viral growth could be a potential therapeutic strategy in combating severe influenza pneumonia.

NETs are released from neutrophils through a cell death mechanism called NETosis and contain DNA fibers decorated with histones and cytosolic proteins. Persistent accumulations of neutrophils and NETs exacerbate alveolar-capillary damage leading to vascular leak and edema that ultimately results in respiratory failure in mice challenged with a lethal influenza virus [11]. Extracellular traps occlude small airways and blood vessels causing epithelial and endothelial damage within the infected areas of the lung [11]. Further, our initial findings using a mouse lethal influenza infection model demonstrated two possible ways controlling neutrophils/NETs mediated-injury in lethal influenza infection. Extracellular histones released during influenza, are functionally active, induce cytotoxicity in alveolar epithelial and endothelial cells evaluated by lactate dehydrogenase release assay; promote microvascular thrombosis in pulmonary vasculature in vivo. Blocking of extracellular histones with anti-histone antibodies significantly decreases lung pathology. Use of a combination of anti-histone antibodies together with an anti-viral agent provides significant protection in lethal influenza challenged mice. We also found various chemokine receptors expressions on neutrophils after infection. Blocking neutrophil recruitment using a chemokine receptor antagonists in combination with an anti-viral agent significantly reduce lung pathology, virus titer and improves survival after lethal influenza challenge in mice. Further studies are in progress testing the combination therapy in a swine-influenza infection setting.

Acknowledgement

This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103648.

References
  1. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J (2009) Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 302: 1872-1879. [Ref.]
  2. Short KR, Kroeze EJ, Fouchier RA, Kuiken T (2014) Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14: 57-69. [Ref.]
  3. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, et al. (2003) Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 9: 195-200. [Ref.]
  4. Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353: 2633-2636. [Ref.]
  5. Kash JC, Taubenberger JK (2015) The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 185: 1528-1536. [Ref.]
  6. Fukuyama S, Kawaoka Y (2011) The pathogenesis of influenza virus infections: the contributions of virus and hostfactors. Curr Opin Immunol 23: 481-486. [Ref.]
  7. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, et al. (2011) The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6: e17618. [Ref.]
  8. Taubenberger JK, Morens DM (2008) The Pathology of Influenza Virus Infections. Annu Rev Pathol 3: 499-522. [Ref.]
  9. Ng HH, Narasaraju T, Phoon MC, Sim MK, Seet JE (2012) Doxycyline treatment attenuates acute lung injury in mice infected with highly virulent influenza H3N2 virus: involvement of matrix metalloproteases. Exp Mol Pathol 92: 287-295. [Ref.]
  10. Xu T, Qiao J, Zhao L, Wang G, He G, et al. (2006) Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med 174: 1011-1017. [Ref.]
  11. Narasaraju T, Edwin Y, Ramarperumal S, Ng HH, Poh WP, et al. (2011) Excessive Neutrophils and Neutrophil Extracellular Traps Contribute to Acute Lung Injury of Influenza Pneumonitis. Am J Pathol 179: 199-210. [Ref.]
  12. Anandi NM, Narasaraju T, Prashant R, perumalsamy R, Tan KB, et al. (2013) In vivo and in vitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infection. Front Immunol 4: 56. [Ref.]
  13. Ivan FX, Rajapakse JC, Welsch RE, Rozen SE, Narasaraju T, et al. (2012) Differential pulmonary transcriptomic profiles in murine lungs infected with low and highly virulent influenza H3N2 viruses reveal dysregulation of TREM1 signaling, cytokines and chemokines. Funct Integr Genomics 12: 105-117. [Ref.]
  14. Audrey-Ann L, Narasaraju T, Tan KB, Wang S, Phoon MC, et al. (2014) Caspase-1-deficient mice are more susceptible to influenza pneumonitis. European Journal of Inflammation 12: 117-130. [Ref.]

Download Provisional PDF Here

 

Article Information

Article Type: Opinion Article

Citation: Teluguakula N, Harshini A (2016) Neutrophils as Possible Therapeutic Targets in Severe Influenza Pneumonia. J Infect Pulm Dis 2(2): doi http://dx.doi.org/10.16966/2470-3176.115

Copyright: © Teluguakula N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication history: 

  • Received date: 10 Apr 2016

  • Accepted date: 26 May 2016

  • Published date: 31 May 2016
  •